Why Shares of Avadel Soared This Week
The company got its first FDA approval.
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Received tentative approval for LUMRYZâ„¢ (sodium oxybate) extended-release for oral suspension from FDA on July 18Advancing key activities to potentially...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...
Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZâ„¢ (sodium oxybate) extended-release oral suspension
- Validates the safety profile and clinical efficacy of LUMRYZ - Pursuing strategies to accelerate final approval DUBLIN, Ireland, July 19, 2022 (GLOBE...
Avadel Pharmaceuticals Provides Corporate Update
Pursuing strategies to accelerate final approval of FT218 NDAOptimizing cost structure to fund strategic priorities and extend cash runwayContinuing...